Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to identification of neuropsychological, genetic and
neuroimaging markers and treatment response predictors of attention-deficit/hyperactivity
disorder (ADHD). Participants who take the standardized pharmacotherapy (methylphenidate or
atomoxetine) for ADHD will be observed for 52 weeks. They will do several neuropsychological,
neuroimaging and genetic tests at visit 1~6.